Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral mucositis: time for more studies.

Yesid Alvarado1, Lisa A Bellm, Francis J Giles

  • 1Department of Leukemia, M.D. Anderson Cancer Center, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.

Hematology (Amsterdam, Netherlands)
|July 10, 2003
PubMed
Summary

Oral mucositis (OM), a severe side effect of cancer treatments, lacks approved treatments. This review covers OM pathophysiology, clinical aspects, and emerging therapies like antimicrobials and growth factors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same author

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Blood cancer journal·2026
Same author

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Journal of hematology & oncology·2026
Same author

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Cancer·2026
Same author

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

American journal of hematology·2026

Area of Science:

  • Oncology
  • Oral Medicine
  • Pharmacology

Background:

  • Oral mucositis (OM) is a debilitating condition frequently affecting patients undergoing chemotherapy and/or radiotherapy.
  • Its development involves direct cytotoxic damage, inflammatory processes, and changes in the oral microbiome.
  • Currently, no specific agents are approved for OM prevention or treatment.

Purpose of the Study:

  • To review the current understanding of oral mucositis pathophysiology, clinical presentation, and management strategies.
  • To discuss investigational agents under study for OM treatment and prevention.
  • To highlight the need for incorporating OM-reducing measures in cancer treatment protocols.

Main Methods:

  • Literature review of existing research on oral mucositis.
  • Analysis of current knowledge regarding OM pathophysiology and clinical manifestations.
  • Examination of emerging therapeutic agents, including local antimicrobials, hemopoietic growth factors, and cytokines.

Main Results:

  • The pathophysiology of OM is multifactorial, involving direct cellular damage and secondary inflammatory and microbial changes.
  • Several investigational agents show promise for OM management, targeting different aspects of its development.
  • There is a critical need for effective interventions to mitigate OM's impact.

Conclusions:

  • Oral mucositis remains a significant challenge in cancer care with no approved treatments.
  • Investigational therapies, particularly local antimicrobials and growth factors, offer potential avenues for future management.
  • Integrating OM prevention and treatment strategies into clinical trials is essential for improving patient outcomes.

Related Experiment Videos